ROCHE HOLDING AG |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 237.4 CHF | -2.51% |
|
-0.47% | -8.62% |
| 05-22 | Roche: FDA designation for blood test | CF |
| 05-22 | Roche Gets US FDA Breakthrough Designation For Lipoprotein(a) Test | MT |
| Sales 2024 * | 60.14B 65.74B 90.24B | Sales 2025 * | 63.69B 69.63B 95.57B | Capitalization | 187B 205B 281B |
|---|---|---|---|---|---|
| Net income 2024 * | 13.43B 14.69B 20.16B | Net income 2025 * | 14.9B 16.28B 22.35B | EV / Sales 2024 * | 3.35 x |
| Net Debt 2024 * | 13.78B 15.06B 20.67B | Net Debt 2025 * | 7.83B 8.56B 11.74B | EV / Sales 2025 * | 3.07 x |
| P/E ratio 2024 * |
13.5
x | P/E ratio 2025 * |
12.3
x | Employees | - |
| Yield 2024 * |
4.22% | Yield 2025 * |
4.35% | Free-Float | 88.91% |
More Fundamentals
* Assessed data
More news
Latest transcript on Roche Holding AG
More press releases
More news
| 1 day | -2.51% |
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 49 | 02-12-31 | |
Severin Schwan
CHM | Chairman | 57 | 07-12-31 |
Alan Hippe
DFI | Director of Finance/CFO | 57 | 11-03-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Bernard Poussot
BRD | Director/Board Member | 72 | 15-03-02 |
| Director/Board Member | 59 | - | |
| Director/Board Member | 66 | 95-12-31 |
Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.
Sector
Pharmaceuticals
Calendar
2024-05-29
- Bernstein Strategic Decisions Conference
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
HOLD
Number of Analysts
19
Last Close Price
232.1
CHF
Average target price
279.8
CHF
Spread / Average Target
+20.57%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +38.69% | 723B | |
| +34.28% | 595B | |
| -4.49% | 369B | |
| +20.24% | 332B | |
| +2.12% | 282B | |
| +17.02% | 244B | |
| +9.31% | 208B | |
| -0.35% | 168B | |
| +6.42% | 166B |
- Stock Market
- Equities
- ROG Stock
- RO Stock
